Eikonoklastes Therapeutics has filed a notice of an exempt offering of securities to raise $8,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Eikonoklastes Therapeutics is raising up to $8,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Bruce Halpryn…